The U.S. leads the world in pharmaceutical innovation but a bill pending in the U.S. Senate could jeopardize that, University of Richmond law professor Kristen Osenga writes in a guest column.
Subscribe to continue reading this article.
Already subscribed? To login in, click here.
Originally Published:
